MedTrace Logo

Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics

NCT00290121 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-03-14

No results posted yet for this study

Summary

The purpose of this study is to understand, with the use of functional magnetic resonance imaging, the neural correlates involved in appetite control and the mechanism of weight gain in patients with schizophrenia treated with atypical antipsychotics. We hypothesize that a difference in cerebral activations between weight gaining and non-weight gaining patients will be detected after four months of treatment with olanzapine.

Conditions

Interventions

DRUG

Olanzapine

Sponsors & Collaborators

  • Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal

    collaborator OTHER

  • Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal

    collaborator OTHER

  • Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

    collaborator OTHER

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Université de Montréal

    lead OTHER

Principal Investigators

  • Emmanuel Stip, MD, M.Sc. · Centre de recherche Fernand-Seguin, Université de Montréal

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290121 on ClinicalTrials.gov